KYOWA KIRIN CO LTD

Kyowa Kirin’s new data on KOMZIFTI shows a 60 %+ complete‑response rate in AML, boosting value‑based pricing and market access prospects before generics erode the niche.

Kyowa Kirin Co. Ltd. has made significant strides in its oncology and immunotherapy pipeline, with recent milestones including a $30 million payment for a menin inhibitor collaboration and a Phase III study showing a survival benefit for its mogamul…

Kyowa Kirin’s stock price has declined despite the growing demand for urothelial carcinoma therapies, which the company is well-positioned to capitalize on.

Kyowa Kirin is poised for growth in the interleukin-17 inhibitors market due to expanding indications, therapeutic innovation, and the emergence of advanced biologics.

Kyowa Kirin’s Ziftomenib combination therapy has shown promising results, potentially driving growth in the company’s pipeline and impacting its stock price.

Kyowa Kirin’s stock price has seen significant volatility, but promising clinical data for its investigational menin inhibitor, ziftomenib, is expected to boost investor confidence.

Kyowa Kirin Co Ltd has demonstrated remarkable resilience in turbulent markets, driven by its diversified portfolio and commitment to innovation, positioning it as a leader in the Japanese pharmaceutical industry.

Kyowa Kirin Co Ltd is a Japanese pharmaceutical powerhouse on the rise, driven by strategic investments, cutting-edge research, and innovative treatments that are expected to drive growth and strengthen its market position.

Kyowa Kirin and Amgen announce positive results from the ROCKET Phase 3 clinical trial program for rocatinlimab, a promising therapy for moderate to severe atopic dermatitis.

Kyowa Kirin Co Ltd has announced updates on its partnership with Kura Oncology, including upcoming presentations and submissions for rocatinlimab, a therapy targeting the OX40 receptor.